- Home
- LUCD
as 06-20-2025 4:00pm EST
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 140.7M | IPO Year: | 2021 |
| Target Price: | $3.94 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $1.80 | Next Earning Date: | 08-11-2025 |
| Revenue: | $4,173,000 | Revenue Growth: | 39.89% |
| Revenue Growth (this year): | 91.46% | Revenue Growth (next year): | 213.42% |
Stock Insider Trading Activity of Lucid Diagnostics Inc. (LUCD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Matheis Dennis | LUCD | Director | May 20 '25 | Buy | $1.31 | 700,000 | $915,213.16 | 187,098 |
Latest Lucid Diagnostics Inc. News
LUCD Breaking Stock News: Dive into LUCD Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
MT Newswires
25 days ago
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes
PR Newswire
25 days ago
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
MT Newswires
a month ago
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders
PR Newswire
a month ago
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
GuruFocus.com
a month ago
Lucid Diagnostics Inc (LUCD) Q1 2025 Earnings Call Highlights: Strategic Growth Amid Revenue ...
Zacks
a month ago
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
PR Newswire
a month ago
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Compare LUCD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUCD Lucid Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.